Terms: = Germ cell tumor AND PMS1, hPMS1, 5378, ENSG00000064933, PMSL1, HNPCC3, DKFZp781M0253 AND Treatment
6 results:
1. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
[TBL] [Abstract] [Full Text] [Related]
2. Uncover DNA damage and repair-related gene signature and risk score model for glioma.
Wu Y; Liu L; Huang D; Li Z; Xu R; Cheng M; Chen L; Wang Q; You C
Ann Med; 2023 Dec; 55(1):2200033. PubMed ID: 37086071
[TBL] [Abstract] [Full Text] [Related]
3. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract] [Full Text] [Related]
4. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas.
Rellecke P; Kuchelmeister K; Schachenmayr W; Schlegel J
J Neurosurg; 2004 Oct; 101(4):653-8. PubMed ID: 15481721
[TBL] [Abstract] [Full Text] [Related]
6. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract] [Full Text] [Related]
